New hope against drug-resistant lung bacteria? rifabutin trial begins
NCT ID NCT07514364
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the antibiotic rifabutin can improve treatment for people with a stubborn lung infection caused by Mycobacterium abscessus that has become resistant to the common antibiotic clarithromycin. Researchers will enroll 60 adults with active lung disease and measure how well rifabutin works. The goal is to find a better way to control this difficult-to-treat infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM ABSCESSUS LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••